Q2 2026 Ionis Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Ionis Pharmaceuticals Inc (IONS) achieved a significant milestone with the FDA approval of TRYNGOLZA, the first and only medicine to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia.
- The company is experiencing strong commercial momentum with TRYNGOLZA and DAWNZERA, with TRYNGOLZA prescriptions starting on the day of approval.
- Ionis Pharmaceuticals Inc (IONS) is advancing its leadership in neurological diseases with the anticipated launch of Zilganerse, positioned as the first disease-modifying treatment for Alexander's disease.
- The company reported strong financial results with significant year-over-year revenue growth of 56% in the second quarter and 69% in the first half of the year.
- Ionis Pharmaceuticals Inc (IONS) maintains a robust pipeline with promising wholly-owned and partnered programs, including Bepirovirsen for chronic hepatitis B, which is on track for a global launch this year.
- The company faced a setback with the cardio transform Phase 3 study for eplontersen in ATTR cardiomyopathy, which did not meet the primary efficacy endpoint in the overall population.
- There are challenges in gaining payer coverage for TRYNGOLZA, with most early coverage being through medical exceptions.
- The launch of TRYNGOLZA for severe hypertriglyceridemia is expected to be a gradual build, requiring time to educate healthcare providers and patients.
- Ionis Pharmaceuticals Inc (IONS) anticipates increased operating expenses in 2026, driven by commercialization efforts and pipeline advancements.
- The company faces potential pressure on achieving cash flow breakeven by 2028 if certain pipeline programs, like pelacarsen, do not meet expectations.
Good morning and welcome to Ionis second-quarter 2026 financial results conference Call. As a reminder, this call is being recorded.
At this time, I would like to turn the call over to Wade Walke, Senior Vice President of Investor Relations, to lead off the call. Please go ahead.
Thank you, Andrea. Before we begin, I encourage everyone to go to the Investors section of the Ionis website to view the press release and related financial tables we will be discussing today, including a reconciliation of GAAP to non-GAAP financials. We believe non-GAAP financial results better represent the economics of our business and how we manage our business. We've also posted slides on our website that accompany today's call.
With me this morning are Brett Monia, Chief Executive Officer; Kyle Jenne, Chief Global Product Strategy Officer; Holly Kordasiewicz, Chief Development Officer; and Beth Hougen, Chief Financial Officer; Eugene Schneider, Chief Clinical Development Officer; and Eric Swayze,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
